Vertex Software faces strong competition and slower growth, leading to a neutral rating. See why VERX stock remains pricey ...

Scientists have debated where Prototaxites belong in the tree of life for over a century, but now a new study suggests it ...

Zimislecel, Vertex’s investigational fully differentiated islet cell therapy with standard immunosuppression, is in the Phase 3 portion of the ...

Vertex Pharmaceuticals (VRTX) announced several updates on the company’s type 1 diabetes portfolio. Vertex has completed enrollment and dosing ...

Vertex Pharmaceuticals is flexing its innovation muscles beyond its cystic fibrosis stronghold, charging into new territories ...

The diabetes market is booming, with continuous glucose monitoring (CGM) and GLP-1 drugs leading the charge in innovation and ...

Vertex Pharmaceuticals Incorporated VRTX stock has plunged 25.3% this year so far against the industry’s 5.4% increase. VRTX ...

Read Our Latest Stock Report on VERX Vertex Stock Down 3.3 % Shares of NASDAQ:VERX opened at $32.88 on Friday. The stock has a market capitalization of $5.13 billion, a P/E ratio of 182.67, a PEG ...

T he past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX).The biotech won approval for its first cystic fibrosis (CF) drug -- Kalydeco -- back in 2012 and has since ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...